Breath of Innovation®
Verona Pharma is developing life enhancing treatments for respiratory diseases.
November is COPD Awareness Month and World COPD Day.
November is COPD Awareness Month and World COPD Day. Verona Pharma is raising awareness of this serious unmet need along with the American Lung Association and Asthma + Lung UK. Find out more about these support groups here
We’re a clinical‑stage biopharmaceutical company focused on developing and commercializing innovative prescription medicines.
We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker.
The unmet need
→COPD
Cystic Fibrosis
Asthma
Chronic Obstructive Pulmonary Disease is a progressive respiratory disease without a cure.
The condition causes loss of lung function, hospitalizations and death. COPD affects approximately 384 million people worldwide. It is the third leading cause of death globally, according to the Global Initiative for Chronic Obstructive Pulmonary Disease.
Find out moreLatest news
Latest Film
Ensifentrine is a Phase 3, first-in-class candidate for the maintenance treatment of COPD
Verona Pharma
Investor Information
© Verona Pharma plc 2022. All rights reserved
Ensifentrine (RPL554): Mechanism of action
Ensifentrine is a Phase 3, first-in-class candidate for the maintenance treatment of COPD.